Beam Therapeutics Inc. BEAM

BEAM Company Overview

Beam Therapeutics Inc. is a biotechnology company focused on the development of precision genetic medicines using base editing technology, a form of genome editing that enables targeted single-letter DNA changes without creating double-strand breaks. The company operates within the biotechnology and genomic medicine industries, with a primary emphasis on treating serious genetic diseases where current therapeutic options are limited or nonexistent.

Beam’s core business centers on discovering, developing, and commercializing therapies based on its proprietary base editing platform, which is designed to correct disease-causing genetic mutations at the DNA level. Its leading programs target rare genetic diseases, hematologic disorders, and liver-related conditions, with a pipeline that includes both ex vivo and in vivo therapies. The company was founded in 2017 by pioneers in genome editing, including David Liu, and was established to commercialize base editing technology originating from academic research. Beam completed its initial public offering in 2020 and has since expanded its research pipeline and strategic collaborations.